article thumbnail

Redefining Acceleration of the Drug Development Journey

PPD

billion in 2023 to 1.2 From an aging population increasing health care demand to urgent, unmet medical needs, there are clear drivers to advance safe and effective medicines to patients faster than ever. billion in 2035.

article thumbnail

Strategic planning in ADC development: insights from Lonza

Drug Target Review

Each stage must adhere to strict quality and regulatory standards, even before considering fill-finish and packaging. In 2023, Lonza took a significant step forward with the acquisition of Synaffix, bringing new proprietary technologies into the fold and enabling Lonza to offer cutting-edge, site-specific conjugation technologies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Visual Guide to Genome Editors

Codon

The treatment, now known as Casgevy, became the first CRISPR-based therapy to gain FDA approval, in 2023. pyogenes protein — whose compactness makes them far easier to package into viral vectors and deliver into the human body. in late 2023 to treat the genetic blood disorders sickle cell anemia and beta thalassemia.

DNA 81
article thumbnail

Levers for Biological Progress

Codon

bioRxiv (2023). They engineered genetically-encoded RNA exporters, based on viruses, that package and secrete RNA molecules in protective nanoparticles, allowing non-destructive monitoring of those RNA molecules in real-time. Credit: Shaib A.H.

DNA 132
article thumbnail

Lexeo to help launch spinout around RNA drugs for the heart

BioPharma Drive: Drug Pricing

The company has faced some bumps along the way, including a smaller-than-projected IPO in 2023. Lexeo will assess the drug’s efficacy by measuring levels of a protein called frataxin and reductions in left ventricular mass index, under an agreement with the Food and Drug Administration on the design of a planned registrational study.

RNA 219
article thumbnail

Limited Evidence for Nalfmefene

Common Sense for Drug Policy Blog

The only studies reported in the FDA package inserts for both products are pharmacokinetic studies in healthy volunteers, which demonstrated substantially higher naloxone plasma levels than standard doses of naloxone (0.4 In 2023, the FDA approved a 2.7 mg IM vs. 8 mg IN and 2 mg IM vs. 5 mg IM, respectively).

article thumbnail

Baxter Releases Annual Corporate Responsibility Report Highlighting Global Impact

The Pharma Data

reduction in Scope 1 and 2 greenhouse gas (GHG) emissions compared to 2023, and an 18.8% This pilot effort included employee training on circularity principles and identified ways to apply these concepts to manufacturing and packaging. In 2024, the company reported a significant 13.5% decrease from its 2020 baseline.